Ownership of Study Data. Subject to Principal Investigator’s right to use Study Data to publish the results of the Study (see Section 15, Publications), Pfizer is the exclusive owner of all Study Data.
a. Vlastnictví Studijních údajů. S výhradou práva Hlavního zkoušejícího na použití Studijních údajů k publikaci výsledků Studie (viz článek 15, Publikace) je výlučným vlastníkem všech Studijních údajů společnost Pfizer.
Ownership of Study Data. BMS shall own the Study Data to the extent that it relates exclusively to the BMS Study Drug (“BMS Study Data”), and the Recipient shall own the Study Data to the extent that it relates exclusively to the Recipient Study Drug (“Recipient Study Data”). Both Parties shall jointly own any Study Data that does not relate exclusively to the Recipient Study Drug or the BMS Study Drug (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same.
Ownership of Study Data. Corvus shall own all right, title and interest in and to Study Data from the single agent arm of the Study and such Study Data shall be deemed Corvus Confidential Information. Corvus and Genentech shall [***]. Genentech has the right to [***].
Ownership of Study Data. BMS shall own the Study Data to the extent that it relates exclusively to the BMS Compound (“BMS Study Data”), and Exelixis shall own the Study Data to the extent that it relates exclusively to the Exelixis Compound (“Exelixis Study Data”). The Parties shall jointly own (BMS to own 50% and Exelixis to own 50%) any Study Data that does not relate exclusively to the Exelixis Compound or the BMS Compound (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same.
Ownership of Study Data. Institution shall retain and store Medical Records. The Institution will assign, and ensure and procure that Study Staff will assign, to Sponsor all of its rights, title and interest, including intellectual property rights, to all Confidential Information (as defined below) and any other Study Data.
Ownership of Study Data. Notwithstanding anything to the contract in Section 4.2, Krele shall own all work product, information and data arising from the Feasibility Study regardless of whether the Option is exercised.
Ownership of Study Data. Subject to Principal Investigator’s right to use Study Data to publish the results of the Study (see Section 15, Publications) and a non-exclusive license that
a. Vlastnictví Studijních údajů. S výhradou práva Hlavního zkoušejícího na použití Studijních údajů k publikaci výsledků Studie (viz článek 15, Publikace) a nevýhradní licence, která allows certain uses (see Section
11.1. b below), Pfizer is the exclusive owner of all Study Data, and may share Study Data and results with other parties that may have contractual rights to develop Pfizer’s Pharmaceuticals (for example through a license, cooperation agreement, joint support agreement, joint development agreement, etc. with Pfizer). umožňuje určité použití (viz kapitola 11.1.b, níže) je výlučným vlastníkem všech Studijních údajů společnost Pfizer a může sdílet Studijní údaje a výsledky s jinými stranami, které mohou mít smluvní práva na rozvoj Léčiva společnosti Pfizer (například prostřednictvím licence, dohody o spolupráci, dohody o společné podpoře, dohody o společném rozvoji, atd se společností Pfizer).
Ownership of Study Data. As between Novartis and Olema, (a) Novartis shall own the particular Study Data that relate exclusively to the Novartis Study Drugs (“Novartis Study Data”), and Olema shall own the particular Study Data that relate exclusively to Olema Study Drug (“Olema Study Data”), and (b) both Parties shall jointly own any and all Study Data that is not Olema Study Data or the Novartis Study Data (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, its right, title and interest in and to any Study Data as is necessary to fully effect the foregoing ownership, and agrees to execute all instruments as may be reasonably necessary to effect same.
Ownership of Study Data. BMS shall own the Study Data to the extent that it relates solely to the BMS Compound (“BMS Study Data”), and Checkmate shall own the Study Data to the extent that it relates solely to the Checkmate Compound (“Checkmate Study Data”).
Ownership of Study Data. Nektar shall own the Study Data to the extent that it relates exclusively to the Nektar Compound (“Nektar Study Data”), and BioXcel shall own the Study Data to the extent that it relates exclusively to the BioXcel Compound (“BioXcel Study Data”). Both Parties shall jointly own any Study Data that does not relate exclusively to the BioXcel Compound or the Nektar Compound (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same. Nektar shall have the right to disclose the Combined Therapy Study Data to BMS, and BMS shall have the right to use the Combined Therapy Study Data as provided in the SCA; provided that Nektar shall not disclose any confidential information of the CPI Compound supplier CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WHERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. in connection therewith, including any data, results or information relating solely to the CPI Compound or any pharmacokinetic information relating to the CPI Compound (to be clear, nothing in the foregoing proviso shall prohibit Nektar from disclosing the Combined Therapy Study Data to BMS on the terms provided herein).
